ICER: Majority of payer coverage policies support 'key elements of fair access' in formularies
The cost-effectiveness watchdog ICER took a look at 19 drugs and compared them to payer coverage policies — finding in its newest report that payers, more often than not, align with certain criteria of fair access.
The 46-page final report published Tuesday examined drugs such as Roche’s Hemlibra, J&J’s Remicade and Stelara, and AbbVie’s Humira and compared them to coverage policies from 18 formularies, including the 15 largest commercial formularies, the formulary for the Veterans Health Administration and the formularies of the two largest state ACA exchange plans.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.